Editas Medicine Inc. EDIT was a big mover last session, as the company saw its shares rise over 10.6% on the day. The news led to far more shares changing hands than in a normal session, resulting in solid volume. This breaks the recent trend for the company as the stock is now down 6.8% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower, suggesting trouble down the road. So, make sure to keep an eye on this stock going forward to see if yesterday’s move higher can last.
Editas Medicine has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
A better-ranked stock in the same industry is Anika Therapeutics Inc. ANIK, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EDIT going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANIKA THERAPEUT (ANIK): Free Stock Analysis Report
EDITAS MEDICINE (EDIT): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research